First Author: Y.Toklu TURKEY
Co Author(s): M. Arıkan Yorgun H.B. Çakmak M. Mutlu S. Uysal N. Çağıl 0 0 0 0 0 0 0 0 0
Back to previous
To report a rare case of a patient who presented with acute endophthalmitis following sustained-release dexamethasone intravitreal implant for branch retinal vein occlusion (BRVO).
Acute endophtalmitis is a rare complication after sustained-release dexamethasone intravitreal implant
A 58-year-old man admitted to our opthalmology department with the complaint of BRVO. Best-corrected visual acuity (BCVA) in the right eye was 0.2. He was treated with intravitreal Ozurdex® in the right eye. Two days after the injection, the patient presented with ocular pain and the visual acuity was hand movement. A diagnosis of endophthalmitis was made.
We performed emergent 23 gauge pars plana vitrectomy (PPV) and the implant was removed from the vitreous cavity using a retinal forceps. A combination of vancomycin 1.0 mg and amikacin 0.4 mg was injected intravitreally. However, because of the blurring in the vitreus one week after the procedure, phacoemulsification and a repeat PPV was performed. Five days after the last procedure the signs and symptoms of endophthalmitis were resolved. The final BCVA was 0,05 for the right eye. The results of both aqueous and vitreous cultures are negative.
Our case demonstrated that endophthalmitis could develop after intravitreal implantation of Ozurdex. Surgical removal of the implant and immediate vitrectomy seems to be a useful treatment option in these cases.